Activities of daily life, education, and employment were areas of difficulty in the transition to adulthood for patients with ...
Givinostat should be available to people with Duchenne muscular dystrophy through a type of compassionate use scheme.
ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...
Hosted on MSN2d
FDA removes clinical hold on Entrada’s Duchenne therapyEntrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...
4d
Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...
Research and development (R&D) expenses: R&D expenses were $81.8 million and $58.8 million for the quarters ended December 31, 2024 and 2023, respectively. R&D expenses were $281.4 million and $210.8 ...
DMD Systems Recovery, LLC (DMD) proudly announces its recognition on the 2025 MO 100 Top Impact CEO Ranking for the third consecutive year, reinforcing its commitment to sustainable and responsible ...
Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...
Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...
Dr. Ritu Manchanda earned her B.D.S. from Bharti Vidyapeeth Dental College, Pune, India. She then received her D.M.D. from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback